Difference between revisions of "Glioblastoma"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) (→General: who 2016 update) |
Jensflorian (talk | contribs) (→IHC: secondary GBM) |
||
| Line 130: | Line 130: | ||
*[[MAP2]] +ve. | *[[MAP2]] +ve. | ||
*[[IDH-1]] -ve (95%). | *[[IDH-1]] -ve (95%). | ||
**+ve if developed from lower grade astrocytoma (secondary GBM). | **+ve if developed from lower grade astrocytoma (secondary GBM) -> classify tumor as Glioblastoma, IDH-mutant. | ||
*[[WT-1]] +ve (cytoplasm). | *[[WT-1]] +ve (cytoplasm). | ||
*p53 +ve (70%). | *p53 +ve (70%). | ||
| Line 137: | Line 137: | ||
*panCK -ve (except for GBM with epithelial component). | *panCK -ve (except for GBM with epithelial component). | ||
*[[ATRX]]: +ve (no loss, nuclei) | *[[ATRX]]: +ve (no loss, nuclei) | ||
**-ve if developed from lower grade astrocytoma (secondary GBM). | **-ve if developed from lower grade astrocytoma (secondary GBM). | ||
*EMA: Dot-like expression less common than in [[ependymoma]]s. | *EMA: Dot-like expression less common than in [[ependymoma]]s. | ||
*MIB-1 usu. 15-30%, but varies greatly. | *MIB-1 usu. 15-30%, but varies greatly. | ||